Bifidobacterium lactis is a Gram-positive, anaerobic, non spore forming rod shaped bacterium.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBGF-0722-GF60 |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium lactis is a Gram-positive, anaerobic, non spore forming rod shaped bacterium. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Application | Study and research |
Culture Medium | BBL |
Culture Conditions | 37°C; Anaerobic |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS. |
Alternative Names | Bifidobacterium lactis |
The dosage can vary depending on the study, but commonly, it ranges from 1 to 10 billion CFUs per day. The exact dosage should be determined based on the specific objectives of the research and the target population.
Bifidobacterium lactis thrives under anaerobic conditions at a temperature range of 37°C. The pH of the growth medium should be maintained around 6.5 to optimize bacterial proliferation and metabolic activity.
Bifidobacterium lactis is stable in various formulations, including dairy products and dietary supplements. Encapsulation techniques can enhance its stability by protecting the bacteria from environmental stresses during processing and storage.
Bifidobacterium lactis cultures should be prepared using freshly prepared, pre-reduced media under anaerobic conditions. The media should be devoid of oxygen to maintain the viability of the bacteria.
Common challenges include maintaining anaerobic conditions, preventing contamination, and ensuring consistent growth. Using high-quality, pre-reduced media and strict anaerobic techniques can help mitigate these challenges.
Concentration of TNF-a and IL-6 in the control (CONT) and probiotic (PROB) groups evaluated at the beginning of the study (T0) and after 45 d (T45) of milk ingestion
The study evaluated the effects of Bifidobacterium lactis HN019 on lipid profiles and cytokine levels in patients with metabolic syndrome (MetS). Fifty-one participants with MetS were divided into two groups: a control group (n=25) and a probiotic group (n=26) who consumed 80 mL of fermented milk containing B. lactis HN019 daily for 45 days. The results showed significant improvements in the probiotic group compared to the control group. There was a marked reduction in body mass index (BMI) (P=0.017), total cholesterol (TC) (P=0.009), and low-density lipoprotein cholesterol (LDL-C) (P=0.008). Furthermore, significant decreases in pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) (P=0.033) and interleukin-6 (IL-6) (P=0.044), were observed in the probiotic group.
These findings suggest that B. lactis HN019 can positively influence lipid metabolism and reduce inflammation in individuals with MetS, thus potentially lowering cardiovascular risks. The reduction in BMI, TC, and LDL-C, coupled with the decreased levels of TNF-α and IL-6, underscores the therapeutic potential of B. lactis HN019 in managing metabolic syndrome.
Bernini, L. J., Simão, A. N. C., et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016, 32(6): 716-719.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.